Utility of [11C]4DST PET in assessing malignancy of tumors

Utility of [11C]4DST PET in assessing malignancy of tumors - Utility of [11C]4DST PET in assessing malignancy of tumors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035956

Enrollment

Registered

2019-02-21

Start date

2017-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain tumor, head and neck cancer, lung cancer, liver cancer, biliary tract cancer, pancreas cancer, musculoskeletal tumor, prostate cancer

Interventions

[11C]4DST PET/CT FDG PET/CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have malignant tumors or are suspected to have malignant tumors. 2) Patients who agree and write informed consent form

Exclusion criteria

Exclusion criteria: 1) Patients who are assumed to be difficult to implement the PET/CT examination due to general condition etc. 2) Women who are pregnant 3) Other patients who are judged inappropriate by research researcher, etc.

Design outcomes

Primary

Measure	Time frame
[11C]4DST uptake in tumors (visual assessment, SUV quantification, uptake count)	—

Secondary

Measure	Time frame
1) histological malignancy 2) FDG uptake in tumors	—

Countries

Japan

Contacts

Public ContactYoshihiro Eto

Southern TOHOKU Research Institute for Neuroscience Corporate head office

yoshihiro.eto@mt.strins.or.jp024-934-5322

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026